Stocks soared on Tuesday as investors returned after the Monday holiday. The optimism seemed to be buoyed by optimistic results from a couple of different COVID-19 vaccines.
All four indices gained ground on the day, but they did close off of their highs. The Russell led the way with a gain of 2.77% and it was followed by the Dow with a gain of 2.17%.
The S&P turned lower in the last half hour but still managed to post a gain of 1.23% and the Nasdaq eked out a gain of 0.17% after moving in to negative territory late in the day.Eight of the 10 sectors posted gains on the day while tech and healthcare were the only two that lost ground.
The healthcare sector dropped 0.18% and the tech sector fell 0.10%.
The financial sector posted a monster gain of 5.2% to lead the way and the industrial sector jumped 4.2% as the second best performer. Energy gained 2.78% and the materials sector gained 2.74%.
My scans continued to turn more negative with 88 bearish signals and nine bullish signals on Tuesday.
The barometer dropped to -60.4 from -42.1 once these results were added in.
Given the huge discrepancy between the two lists, I found far more bearish setups that liked than bullish ones. The one I felt gave us the best odds of success was on Bluebird Bio Inc. (Nasdaq: BLUE). The stock was on the bearish list and its fundamental scores are terrible. The EPS rating is a 12 and the SMR rating is an E.
The daily chart shows the steep descent for the stock. It was trading above $140 last July and it was above $235 in 2018. It’s now struggling to get back above the $70 level. The highs over the last year connect to form a downward sloped trend line and the stock hit that trend line last week. The stock dropped sharply yesterday as the resistance seemed to hold.
Buy to open the July 70-strike puts on BLUE at $11.70 or better. These options expire on July 17. I suggest a target gain of 70% which means the stock will need to drop down to the $50 area. The low on May 1 was right in this area, so the stock won’t have to break to the March low to hit our target. I recommend a stop at $70.50.
— Rick Pendergraft
Nvidia's Secret Partner... This Is The New AI Chip Powerhouse [sponsor]I bet you've never heard of it... but this newly public company is set to become key to Nvidia's seat on the AI throne. And for now... you can get in while it's still cheap. Details Here! Find Out What It Is Right Here.